ADAG – Adagene Inc.
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ADAG#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
ADAG — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
5.19
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
-0.21
EPS This/Next Y
-0.01
Price
4.14
Target Price
12.72
Analyst Recom
1
Performance Q
14.8
Upside
-217.0%
Beta
0.59
Ticker: ADAG
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | ADAG | 3.81 | N/A | N/A | 0 |
| 2026-07-14 | ADAG | 3.6 | N/A | N/A | 0 |
| 2026-07-15 | ADAG | 3.66 | N/A | N/A | 0 |
| 2026-07-16 | ADAG | 3.58 | N/A | N/A | 0 |
| 2026-07-17 | ADAG | 3.57 | N/A | N/A | 0 |
| 2026-07-20 | ADAG | 3.61 | N/A | N/A | 0 |
| 2026-07-21 | ADAG | 3.67 | N/A | N/A | 0 |
| 2026-07-22 | ADAG | 3.59 | N/A | N/A | 0 |
| 2026-07-23 | ADAG | 3.38 | N/A | N/A | 0 |
| 2026-07-24 | ADAG | 3.17 | N/A | N/A | 0 |
| 2026-07-27 | ADAG | 3.52 | N/A | N/A | 0 |
| 2026-07-28 | ADAG | 3.73 | N/A | N/A | 0 |
| 2026-07-29 | ADAG | 3.69 | N/A | N/A | 0 |
| 2026-07-30 | ADAG | 3.73 | N/A | N/A | 0 |
| 2026-07-31 | ADAG | 3.76 | N/A | N/A | 0 |
| 2026-08-03 | ADAG | 3.63 | N/A | N/A | 0 |
| 2026-08-04 | ADAG | 3.64 | N/A | N/A | 0 |
| 2026-08-05 | ADAG | 4.24 | N/A | N/A | 0 |
| 2026-08-06 | ADAG | 4.1 | N/A | N/A | 0 |
| 2026-08-07 | ADAG | 4.14 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | ADAG | 3.83 | - | - | -0.51 |
| 2026-07-14 | ADAG | 3.61 | - | - | -0.51 |
| 2026-07-15 | ADAG | 3.65 | - | - | -0.51 |
| 2026-07-16 | ADAG | 3.60 | - | - | -0.51 |
| 2026-07-17 | ADAG | 3.60 | - | - | -0.51 |
| 2026-07-20 | ADAG | 3.64 | - | - | -0.51 |
| 2026-07-21 | ADAG | 3.68 | - | - | -0.51 |
| 2026-07-22 | ADAG | 3.62 | - | - | -0.51 |
| 2026-07-23 | ADAG | 3.38 | - | - | -0.51 |
| 2026-07-24 | ADAG | 3.17 | - | - | -0.51 |
| 2026-07-27 | ADAG | 3.50 | - | - | -0.51 |
| 2026-07-28 | ADAG | 3.75 | - | - | -0.51 |
| 2026-07-29 | ADAG | 3.68 | - | - | -0.51 |
| 2026-07-30 | ADAG | 3.74 | - | - | -0.51 |
| 2026-07-31 | ADAG | 3.74 | - | - | -0.51 |
| 2026-08-03 | ADAG | 3.64 | - | - | -0.51 |
| 2026-08-04 | ADAG | 3.64 | - | - | -0.51 |
| 2026-08-05 | ADAG | 4.23 | - | - | -0.51 |
| 2026-08-06 | ADAG | 4.12 | - | - | -0.51 |
| 2026-08-07 | ADAG | 4.14 | - | - | -0.51 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | ADAG | 0.00 | 23.59 | 4.94 |
| 2026-07-14 | ADAG | 0.00 | 23.59 | 4.94 |
| 2026-07-15 | ADAG | 0.00 | 23.59 | 4.94 |
| 2026-07-16 | ADAG | 0.00 | 23.59 | 4.94 |
| 2026-07-17 | ADAG | 0.00 | 23.59 | 4.94 |
| 2026-07-20 | ADAG | 0.00 | 22.55 | 4.94 |
| 2026-07-21 | ADAG | 0.00 | 22.55 | 4.94 |
| 2026-07-22 | ADAG | 0.00 | 22.55 | 4.94 |
| 2026-07-23 | ADAG | 0.00 | 22.55 | 4.94 |
| 2026-07-24 | ADAG | 0.00 | 22.55 | 4.94 |
| 2026-07-27 | ADAG | 0.00 | 15.46 | 5.19 |
| 2026-07-28 | ADAG | 0.00 | 15.46 | 5.19 |
| 2026-07-29 | ADAG | 0.00 | 15.46 | 5.19 |
| 2026-07-30 | ADAG | 0.00 | 15.46 | 5.19 |
| 2026-07-31 | ADAG | 0.00 | 15.46 | 5.19 |
| 2026-08-03 | ADAG | 0.00 | 15.45 | 5.19 |
| 2026-08-04 | ADAG | 0.00 | 15.45 | 5.19 |
| 2026-08-05 | ADAG | 0.00 | 15.45 | 5.19 |
| 2026-08-06 | ADAG | 0.00 | 15.45 | 5.19 |
| 2026-08-07 | ADAG | 0.45 | 15.45 | 5.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ADAG 589 360 ]
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.08
Avg. EPS Est. Next Quarter
-0.19
Insider Transactions
0.45
Institutional Transactions
15.45
Beta
0.59
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
28
Growth Score
40
Sentiment Score
85
Actual DrawDown %
79.1
Max Drawdown 5-Year %
-95.2
Target Price
12.72
P/E
Forward P/E
PEG
P/S
25.33
P/B
5.51
P/Free Cash Flow
EPS
-0.37
Average EPS Est. Cur. Y
-0.51
EPS Next Y. (Est.)
-0.52
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-229.49
Relative Volume
1.22
Return on Equity vs Sector %
-77.1
Return on Equity vs Industry %
-61.1
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.21
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ADAG 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ADAG 589 450 ]
◆
ADAG
Healthcare
$4.11
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
58.9
Range 1M
85.5%
Sup Dist
3.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
46.7%
EPS NY
-12.5%
52W%
79.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+209.5% upside
Upside
+209.5%
Quality
28
ADAG — P/E HistoricalBiotechnology
Adagene Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 128
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG
Latest News
—
Caricamento notizie per ADAG…
stock quote shares ADAG – Adagene Inc. Stock Price stock today
news today ADAG – Adagene Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ADAG – Adagene Inc. yahoo finance google finance
stock history ADAG – Adagene Inc. invest stock market
stock prices ADAG premarket after hours
ticker ADAG fair value insiders trading